News
INCY
57.40
+0.37%
0.21
Incyte Acquires 2 Downtown Wilmington Office Buildings, Expanding Its Presence In Delaware; Financial Terms Not Disclosed
Incyte acquires two buildings in downtown Wilmington, Delaware. This is Incyte's fourth expansion in Delaware since establishing operations in Alapocas in 2014. The new buildings will allow the Company to expand its presence in the state of Delaware.
Benzinga · 11h ago
INCYTE EXPANDS PRESENCE IN DELAWARE THROUGH ACQUISITION OF TWO DOWNTOWN WILMINGTON OFFICE BUILDINGS
Reuters · 11h ago
Incyte to Present at Upcoming Investor Conference
Incyte will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 in Miami. The presentation will be webcast live and will be available for 30 days. Incyte is a global biopharmaceutical company on a mission to Solve On.
Barchart · 21h ago
Weekly Report: what happened at INCY last week (0513-0517)?
Weekly Report · 1d ago
Incyte’s Share Buyback Program: A Buy Rating and Fundamental Value Increase
TipRanks · 5d ago
Incyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold Rating
TipRanks · 6d ago
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
NASDAQ · 6d ago
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
Barchart · 05/14 16:00
Company News For May 14, 2024
NASDAQ · 05/14 13:11
Stock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell Remarks
June S&P 500 E-Mini futures are up + this morning ahead of producer inflation data due later in the day. Incyte Corp. Was the top percentage gainer on the S&p 500 in yesterday's trading session. The German annual inflation rate arrived at in April. Investors are awaiting comments from Federal Reserve Chair Jerome Powell.
Barchart · 05/14 04:33
Incyte’s Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
TipRanks · 05/13 22:46
Incyte Buyback Seen Luring Value Investors -- Market Talk
Incyte announces a $2 billion stock buyback program. The cancer drug Jakafi has a 2029 patent expiration. The patent lapsing would strip Incyte of billions of dollars in potential revenue. Cantor Fitzgerald analyst Eric Schmidt called for the buyback. The company's shares rise.
Dow Jones · 05/13 19:06
BUZZ-U.S. STOCKS ON THE MOVE-Annexon, MKS Instruments, Robinhood
Investors awaited key inflation figures this week to gauge the likelihood of interest rate cuts in 2024. The Dow Jones Industrial Average and the S&P 500 hit record highs on Monday. GameStop Corp was one of the top percentage gainers on the New York Stock Exchange.
Reuters · 05/13 16:09
Stocks Close Little Changed on Caution Ahead of US Inflation Reports
US stocks on Monday settled mixed. Higher inflation expectations and hawkish comments from the Fed weighed on stocks. Incyte Corp and Walgreens Boots Alliance closed up after positive corporate news. The markets will focus on US inflation reports this week. The S&P 500 and other European stock markets closed down on Monday.
Barchart · 05/13 15:40
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
The Dow Jones gained more than 90 points on Monday. Shares of GameStop Corp. Rose sharply amid possible retail investor interest following a social media post by Roaring Kitty. Other big stocks recording gains in today's session include iRobot, Novavax, Wayfair, and AMC Entertainment Holdings.
Benzinga · 05/13 14:22
S&P 500 Movers: MTD, INCY
NASDAQ · 05/13 14:21
Incyte Shares Rally on $2 Billion Buyback Plans
Incyte plans to buy back $2 billion worth of stock. The biopharmaceutical company says it will buy back shares at a price range of $52 to $60 a share. Shares of Incyte rose sharply Monday. The company last month struck a deal to buy a drug company.
Dow Jones · 05/13 14:05
Incyte Up Over 9%, on Pace for Largest Percent Increase Since August 2017 -- Data Talk
Incyte Corporation (INCY) is currently at $ , up $ from yesterday's close. Would be highest close since March 20, 2024, when it closed at $. On pace for largest percent increase since Aug. 30, 2017. Best performer in the S&P 500 today.
Dow Jones · 05/13 13:52
BUZZ-Incyte jumps on $2 bln share buyback plan
Shares of Incyte jump premarket to $ , over 1-mth high, as biopharma firm announces $2 bln stock buyback plan. Co commences modified "Dutch Auction" tender offer to repurchase shares for aggregate purchase price of up to $ bln. Baker Bros Advisors, a top INCY holder, to buy shares in tender offer.
Reuters · 05/13 13:25
Incyte Stock Jumps on 'Dutch Auction' Buyback Plan. How It Works.
Biopharmaceutical company Incyte to buy up to $2 billion worth of its own shares. Incye stock jumped one of the biggest percentage gainers in the S&P 500 in premarket trading Monday. The company sells cancer and inflammation and autoimmune drugs. Share repurchases typically boost share prices and earnings.
Barron‘s · 05/13 13:14
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.